Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts. Here's why. NXE Volatility, as measured by the volatility index (VIX), can bring fear and uncertainty to the stock market, and with those feelings usually come lower prices. So, before they allocate capital, those hunting for a poten ...

Hims & Hers Health, Inc.'s (HIMS) investors are encountering some short-term losses from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have plunged 32.1% in the past three months, underperforming the industry's 11.4% gain. In the same time frame, the stock underperformed the sector and S&P 500's 4.7% and 2.7% growth, respectively. Two major developments from HIMS in recent months include the announcement of its second-quarter 2024 results (in August) and the addition ...

Sales growth could accelerate now that it provides lower-cost, weight-management drugs. If you'd like to become a billionaire, paying attention to how other billionaires invest is a sensible way to get started. Everyday investors can easily keep tabs on billionaire stock purchases because the U.S. Securities and Exchange Commission (SEC) makes them disclose their trading activity every three months. In the latest round of disclosures, it's clear that a handful of funds run by billionaire investors bought sh ...

These businesses are rapidly growing profits and cash flows. You don't need to have a ton of cash on hand to invest. Steadily investing even modest amounts of money and distributing that capital across various stocks through thick and thin in the market can help you compound your returns with time. It's important to understand the business behind any stock you buy. While the recent market volatility is making some investors fearful of putting cash to work, if you have a more modest amount, like $200, you ca ...

A new threat from Eli Lilly pushed the stock lower. Shares of Hims & Hers Health (HIMS 0.61%), the online, direct-to-consumer pharmacy, were pulling back this week as investors feared that pharmaceutical companies could start encroaching on its territory. In particular, Eli Lilly (LLY -0.92%), the maker of popular GLP-1 drugs like Mounjaro, said on Tuesday that it would discount single-dose vials of its Zepbound GLP-1 weight loss drug in response to high demand. The news was seen as a competitive threat to ...

Could a competitor lowering prices eat into Hims & Hers market share? Shares of Hims & Hers (HIMS -7.54%) fell as much as 8% on Tuesday and closed at their low for the day after news broke that Eli Lilly (LLY 0.42%) lowered the price for a key weight loss drug. Eli Lilly's shot at Hims & Hers The big news on Tuesday was an announcement that Eli Lilly will sell the weight loss drug Zepbound through its direct-to-consumer website at a 50% discount to the previous price. A 2.5 milligram single-dose vial will c ...

After a strong start to the year, the stock is down 30% since June. In this video, I will be talking about Hims & Hers' (HIMS -0.60%) recent earnings report and explain why there has been some weakness in the stock. Check out the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices used were from the trading day of Aug. 21, 2024. The video was published on Aug. 22, 2024. ...

greg801/E+ via Getty Images In an odd twist, Hims & Hers Heath, Inc. (NYSE:HIMS) reported booming sales, yet the stock was actually sold hard following earnings. Management of the online ir and view of a new receinting met (1 rosemans) representation weight lose world beath was man hall belowing chamilies. Mangules. Ho downline, Maligenten dio ouline, Malin Ti DAILY | --- | --- | --- | --- | --- | |-------|------------------------|---------|-------|---------------| | | | | | | | | finviz | | | | | | HIMS Au ...

PM Images/DigitalVision via Getty Images Markets appear to have shaken off the fears stemming from U.S. recession talk and the unwinding of the Japan carry trade, but a number of stocks still remain well off their recent highs. Hims & Hers Health, Inc. (NYSE:HIMS), the maker and distributor of generic medicines, is one of the most notable names in this bucket. The stock has been rocked after reporting Q2 results, primarily on concerns that its revenue projections for its GLP-1 weight loss compounds are over ...

Daniel Grizelj Introduction Hims & Hers Health (NYSE:HIMS) has had an outstanding year so far, as the stock price is up 87.73% YTD. Q4'23 earnings gave investors a lot of confidence going forward, as the company exceeded expectations and raised its guidance. Q1'24 earnings also received a great reception, with the company posting great results once again. Weeks later, the company announced it would start selling compounded GLP-1 agonists to subscribers. Investors and the market responded well, as the stock ...